A groundbreaking medical device has attracted a substantial investment, poised to change kidney failure treatments.
Developed by MicroBioSensor, this ‘iPad mini-sized’ device aims to offer early detection of life-threatening infections in peritoneal dialysis patients.
Investment and Initiation of Clinical Trials
MicroBioSensor, a spin-out from the University of Manchester, has obtained £1.4 million in equity finance from the Northern Powerhouse Investment Fund and Catapult Ventures. This investment will enable the commencement of its first clinical trial, marking a pivotal moment for the company. The trial is set to begin and run through to mid-2019, representing a critical step towards enhancing treatment outcomes for individuals undergoing peritoneal dialysis.
Addressing a Critical Issue in Dialysis
The core issue with peritoneal dialysis is the risk of infection within the peritoneal cavity, which can become fatal if not treated promptly. Of the tens of thousands in the UK on renal replacement therapy, fewer than 10% use peritoneal dialysis. Fear of infection is a significant deterrent.
MicroBioSensor’s device integrates with existing dialysis equipment, providing an essential layer of security by detecting early signs of infection. This early detection can potentially extend patients’ time on this valuable form of dialysis.
Design and Functionality of the Device
Drawing on innovative technology, the device is remarkably user-friendly, presenting results through a simple colour code.
If the device registers a pale green colour, it indicates no infection; whereas a shift to dark purple signals a problem, prompting users to seek medical attention promptly.
Dr. Gordon Barker, the company’s CEO, explains, “You are essentially looking at a window on the device for a colour change. If it’s a pale green everything is ok, if it goes to a dark purple colour, you know you have a problem.” This simplicity is crucial for ensuring that non-specialists can operate the device effectively at home.
Potential Healthcare Impact
The successful implementation of this device in clinical settings could lead to significant cost savings for the NHS, as it potentially decreases hospital admissions due to infections.
The vision extends beyond hospitals, aiming for home use by patients, thus reducing the burden on healthcare facilities and empowering patients to manage their health proactively.
Support and Recognition
MicroBioSensor’s journey has also been supported by various forms of transitional funding and grants, underscoring the confidence in its mission.
Notably, it has received £125,000 from UMIP, £100,000 from Spark Impact, and £983,000 from Innovate UK.
Additional recognition came in November when MicroBioSensor won the 2017 Bionow Investment Deal of the Year Award, highlighting its potential impact and innovation in medical technology.
Looking Forward
With the backing of substantial funding and a growing recognition of its innovative approach, MicroBioSensor is well-positioned to advance its mission.
The upcoming clinical trials are crucial and could pave the way for the product’s entry into the market, offering new hope for thousands undergoing dialysis.
Conclusion
The trajectory of MicroBioSensor and its revolutionary device exemplifies the potential of innovative technology in transforming healthcare.
As it moves towards clinical trials and potential market entry, the impact on peritoneal dialysis could be profound, offering increased safety and peace of mind for patients and healthcare providers alike.
The journey of MicroBioSensor reflects a promising future for medical technology innovations, aiming to enhance patient care and safety.
With continued development, this device could become an integral tool in the management of peritoneal dialysis, ultimately improving quality of life.